After hosting investor meetings with management, Citi analyst Ralph Giacobbe believes the financial impact from the coronavirus has been limited for UnitedHealth. Beyond that, the company's underlying cost trends remain well managed, Giacobbe tells investors in a research note. This coupled with Medicare Advantage continuing to show solid growth, Medicaid positioned to improve in 2020, and opportunities across Optum "should all allow strong growth to continue this year," says the analyst, who reiterates a Buy rating on UnitedHealth.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here